Self-funding is the default now. The stop-loss layer has to catch up.
Health In Tech · October 6, 2026
A market this large should not still be placed over email.
For most of the last two decades, self-funding was the plan design a company graduated into once it was big enough to carry the risk. That framing is out of date. In 2025, 67 percent of covered U.S. workers were in a self-funded health plan, according to the KFF Employer Health Benefits Survey. Self-funding is no longer the exception for large employers. It is how most Americans with job-based coverage are now covered.
The pull is easy to understand. A fully insured renewal arrives as a single number with little explanation. Self-funding gives an employer its own claims data, control over plan design, and the ability to keep what it does not spend. The model has also moved down-market. Level-funded plans, the hybrid that pairs a fixed monthly cost with built-in stop-loss protection, reached 37 percent of small firms in 2025 (UnitedHealthcare). A benefits strategy once reserved for the largest employers is now a live option for a 40-life group.
Every one of those plans depends on the same thing. Stop-loss insurance is the layer that turns a self-funded plan from a gamble into a managed risk. It caps what the employer can lose on any one claimant and on the plan as a whole. Get it right and self-funding delivers on its promise. Get it wrong, or place it late, and a single catastrophic claim can undo a year of savings.
The pressure the shift created
Scale brought scrutiny, and the numbers underneath stop-loss have turned sharply. Employer health cost trend for 2026 is projected in the 8.5 to 9.6 percent range across the major benefits consultancies, with Mercer calling it the steepest trend in fifteen years. Trend at that level does not stay in the base plan. It flows straight into the stop-loss layer, where severity concentrates.
Stop-loss pricing shows it. Segal reported that medical stop-loss premiums rose close to 13 percent heading into 2026, up from 9.7 percent the prior year, across its national dataset of more than 200 plans. Industry loss ratios have been running near 91 percent per NAIC data. The line is repricing because the claims behind it are getting larger and more frequent, not because carriers changed their minds.
Two forces sit behind most of that severity. The first is cell and gene therapy. A single course of a therapy like Lenmeldy carries a benchmark cost around 4.2 million dollars (CVS Caremark). One member can consume a mid-size plan's entire annual budget, and the pipeline of seven-figure therapies in late-stage trials means the exposure grows every year. The second is GLP-1 utilization, which now accounts for roughly 21 percent of employer pharmacy spend where the drugs are covered (WTW). Neither of these was a material line item five years ago. Both are permanent variables in stop-loss pricing now.
For the broker, this changes the job. Stop-loss is no longer a commodity you re-market for a few points of savings. It is the part of the plan most exposed to the claims environment, and the part where the quality of the placement shows up fastest.
The weak link is the workflow, not the risk
Here is the part the market does not like to say out loud. The self-funded model modernized. The way stop-loss gets placed did not. A complex large-group case still moves through separate inboxes, PDF proposals, and spreadsheets rebuilt by hand for every market. A broker sends a submission to one carrier or MGU at a time, waits, and rebuilds the comparison each time a response comes back in a different format. Claims data gets re-keyed. Quotes get compared on whatever fields the last carrier happened to send.
That manual process is slow at the exact moment speed matters. When trend is running near double digits and a single laser candidate can swing the price, days spent chasing status and re-formatting spreadsheets are days the market is repricing underneath you. Milliman's 2024 survey of the employer stop-loss market found that predictive modeling is still used by only a minority of underwriters, even as loss ratios climb and brokers expect faster answers. The infrastructure has not kept up with the money moving through it.
It also creates avoidable risk. When comparisons are assembled by hand, the terms that actually move the placement, such as no-new-laser provisions, rate caps, run-in and run-out basis, and disclosure basis, are easy to lose next to the headline premium. The cheapest quote is often not the best contract, and a manual spreadsheet is where that distinction quietly disappears.
A practical playbook for 2026 placements
You do not need new technology to place better cases. Most of the gap closes with discipline. A few habits separate the desks that get sharp quotes from the ones that get penalized at renewal:
Lead with clean, structured data. Provide 24 months of large-claim detail when you have it. Twelve months is table stakes. Underwriters price what they can see, and a clean submission earns a sharper number.
Practice disclosure discipline. Flag gene-therapy candidacy even when no claim has been paid. A discovered omission can tarnish the relationship for years, and transparency at intake prevents post-bind surprises.
Standardize the census on carrier-agnostic templates. Every format variation adds triage time and slows the quote.
Compare on the terms that shape risk, not just premium. Put specific and aggregate pricing side by side with attachment point, contract basis, laser detail, and carve-out coverage for gene therapy and transplant.
Reach more of the market at once. A case shown to one appetite at a time is a case priced without competitive tension.
Matching the infrastructure to the market
Comparing stop-loss proposals is more useful when the contract terms are as visible as the premiums. HitRix keeps a case in one record from submission through placement: a single submission can reach participating MGUs, while proposals received in PDF, Word, or Excel are organized for side-by-side review. Brokers can examine premiums, deductibles, lasers and contract terms together, with quotes, declines and the final placement documented in the case history. Pricing and risk decisions remain with the MGUs and underwriters. For brokers, the value is a clearer view of how each offer changes the employer’s exposure and a stronger basis for explaining a recommendation to the client, without rebuilding every response in a spreadsheet.
If you’re reviewing your stop-loss placement process ahead of 2027 renewals, book a live demo with our team. We can walk through one of your cases, from submission to side-by-side comparison, so you can see how HitRix would fit your workflow.
